<DOC>
	<DOCNO>NCT02538705</DOCNO>
	<brief_summary>The purpose study determine whether pl-vegf165 ( Neovasculgen ) effective treatment ulcer relate diabetic foot syndrome</brief_summary>
	<brief_title>Safety Efficacy Study Neovasculgen ( Pl-VEGF165 ) Gene Therapy Patients With Diabetic Foot</brief_title>
	<detailed_description>This open clinical trial assess therapeutic efficacy pl-vegf165 ( Neovasculgen ) treat ulcer relate diabetic foot syndrome . Each patient undergo several intramuscular injection treatment dose pl-vegf165 ( Neovasculgen ) calf affected extrimity . Study participant first study visit complete study questionnaire , foot assess clinically ulceration . After initial assessment , patient undergo intramuscular injection pl-vegf165 ( Neovasculgen ) calf altered ulcer due diabetic foot syndrome . At three month post-injection , patient complete study questionnaire , foot assess clinically ulceration , foots undergo non-invasive transcutaneous oximetry measurement . At six month post-injection , patient complete study questionnaire , foot assess clinically ulceration undergo non-invasive transcutaneous oximetry measurement .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>obtain voluntary informed consent participation clinical study presence diabetic foot syndrome presence least one active ulcer baseline Any disease , opinion treat physician , affect outcome study Patients addictive disorder substance abuse Pregnancy nurse All exclusion criterion list summary product characteristic ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetic foot syndrome</keyword>
	<keyword>Ulcers</keyword>
</DOC>